ArticleAntimicrobial agents and chemotherapy2014
Population pharmacokinetics and dosing optimization of vancomycin in children with malignant hematological disease.
Article in Antimicrobial agents and chemotherapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04758442 (Optimal Dosing of Vancomycin in an Adult Population of Hemato-oncology), which is not on this map. Cited by 39 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Optimal Dosing of Vancomycin in an Adult Population of Hemato-oncology: a Nomogram Based on a Bayesian Population Model to Predict Initial Dosage of Vancomycin
Who cites it
39 citing papers in PubMed, 2 syntheses or guidelines pooled it, 75 citations in OpenAlex.
- Systematic review and scoring-based selection of pharmacokinetic models for precision dosing of vancomycin in neonates and children.British journal of clinical pharmacology · 2026Pooled it
- Population Pharmacokinetic Models of Vancomycin in Paediatric Patients: A Systematic Review.Clinical pharmacokinetics · 2021Pooled it
- Continuous versus intermittent vancomycin infusions in critically ill children with gram-positive bacterial infections: a randomized controlled trial.BMC infectious diseases · 2026Trial
- Assessment of Vancomycin Pharmacokinetics and Dose Regimen Optimisation in Preterm Neonates.Drugs in R&D · 2020Trial
- Population Pharmacokinetics and Dosing Optimization of Imipenem in Children with Hematological Malignancies.Antimicrobial agents and chemotherapy · 2019Trial
- Population Pharmacokinetics and Dosing Optimization of Ceftazidime in Infants.Antimicrobial agents and chemotherapy · 2018Trial
- Population pharmacokinetics and dosing optimization of cefathiamidine in children with hematologic infection.Drug design, development and therapy · 2018Trial
- Population pharmacokinetics and dosing optimization of teicoplanin in children with malignant haematological disease.British journal of clinical pharmacology · 2015Trial
- Impact of vancomycin administration modality on target attainment in acutely ill children-a propensity score matching analysis.European journal of pediatrics · 2026Article
- Model-informed precision dosing of vancomycin in children 3 months to 18 years of age using Australia-wide data.Antimicrobial agents and chemotherapy · 2026Article
- Evaluation and Improvement of Specialized Vancomycin Pharmacokinetic Models for Pediatric Cardiovascular Intensive Care Unit and Pediatric Oncology Patients.Clinical pharmacokinetics · 2026Article
- Prediction of Vancomycin Area Under the Curve With Trough Concentrations Only: Performance Evaluation of Pediatric Population Pharmacokinetic Models.The Journal of infectious diseases · 2025Article
- Global research on the utilization of population pharmacokinetic model: a bibliometric analysis from 2000 to 2024.Frontiers in pharmacology · 2025Review
- Evaluation of Vancomycin Dose Needed to Achieve 24-Hour Area Under the Concentration-Time Curve to Minimum Inhibitory Concentration Ratio Greater Than or Equal to 400 Using Pharmacometric Approaches in Pediatric Intensive Care Patients.Critical care explorations · 2024Article
- Population pharmacokinetic analysis for dose regimen optimization of vancomycin in Southern Chinese children.CPT: pharmacometrics & systems pharmacology · 2024Article
- Extended Infusion of Beta-Lactams and Glycopeptides: A New Era in Pediatric Care? A Systematic Review and Meta-Analysis.Antibiotics (Basel, Switzerland) · 2024Review
- Toward Model-Based Informed Precision Dosing of Vancomycin in Hematologic Cancer Patients: A First Step.Clinical pharmacokinetics · 2024Article
- Article
- Use of Machine Learning for Dosage Individualization of Vancomycin in Neonates.Clinical pharmacokinetics · 2023Article
- Population Pharmacokinetics and Pharmacodynamics of Vancomycin in Pediatric Patients With Various Degrees of Renal Function.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An increase in vancomycin dose has been proposed in adults with malignant hematological disease. As pediatric data are limited, our aim was to evaluate the population pharmacokinetics of vancomycin in order to define the appropriate dosing regimen in children with malignant hematological disease. Vancomycin concentrations were collected prospectively during therapeutic monitoring. Population pharmacokinetic analysis was performed using NONMEM software. Seventy children (age range, 0.3 to 17.7 years) were included. With the current recommended dosing regimen of 40 to 60 mg/kg/day, 53 children (76%) had subtherapeutic steady-state trough concentrations (Css/min of <10 mg/liter). A one-compartment model with first-order elimination was developed. Systematic covariate analysis identified that weight significantly influenced clearance (CL) and volume of distribution (V) with power functions of 0.677 for CL and 0.838 for V. Vancomycin CL also significantly increased with increases in creatinine clearance and seemed to be higher in children with malignant hematological disease than in the general pediatric population. The model was validated internally. Its predictive performance was further confirmed in an external validation by Bayesian estimation. A patient-tailored dosing regimen was developed based on the final pharmacokinetic model and showed that a higher proportion of patients reached the target Css/min than with the traditional mg/kg-basis dose (60% versus 49%) and that the risks associated with underdosing or overdosing were reduced. This is the first population pharmacokinetic study of vancomycin in children with malignant hematological disease. An optimized dosing regimen, taking into account patient weight, creatinine clearance, and susceptibility of the pathogens involved, could routinely be used to individualize vancomycin therapy in this vulnerable population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.